Don't Believe the Hype; Remdesivir in the Treatment of COVID-19 .

Remdesivir quickly became one of the most talked-about COVID-19 treatments, supported by an emergency authorization and heavy national investment. Yet when the evidence is examined through a GRADE lens, confidence in its benefit is far less certain than many guidelines imply. Trial data show mixed effects on mortality and only modest signals for faster recovery, with no major safety advantage. This explains why some guidelines issue only weak recommendations while others appear more confident—the difference largely reflects how each panel weighs limited evidence, uncertain benefit, and the value placed on acting quickly during a crisis. Ultimately, remdesivir aligns best with a cautious, weak recommendation until stronger and more consistent data emerge.